- |||||||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion, Trial completion date, Metastases: NIFTY: Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Aug 24, 2022 P2, N=178, Completed, The serum MicroRNA let-7c level was found to be an independent predictive biomarker in the FOLFIRINOX treatment group. Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Dec 2021
- |||||||||| nisevokitug (NIS793) / Novartis
Enrollment open: FOLFIRINOX + NIS793 in Pancreatic Cancer (clinicaltrials.gov) - Aug 23, 2022 P1, N=50, Recruiting, Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Dec 2021 Not yet recruiting --> Recruiting
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Wait until he hears FOLFIRI!!!🔥 (Twitter) - Aug 22, 2022
- |||||||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial completion date, Trial primary completion date, Metastases: PRODIGE 59 - DURIGAST: Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 22, 2022 P2, N=107, Active, not recruiting, Further studies are needed to optimize MTX dose along with FA, VES and MSA. Trial completion date: Jul 2024 --> Feb 2023 | Trial primary completion date: Nov 2023 --> Mar 2022
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Interplay Between Chemotherapy-Activated Cancer Associated Fibroblasts and Cancer Initiating Cells Expressing CD44v6 Promotes Colon Cancer Resistance. (Pubmed Central) - Aug 22, 2022 These findings have crucial clinical implications suggesting that therapeutic approaches for modulating tumor growth that currently focus on cell-autonomous mechanisms may be too limited and need to be broadened to include mechanisms that recognize the interplay between the stromal factors and the subsequent CIC-immunophenotype enrichment. Thus, more specific therapeutic approaches may be required to block a chemotherapy induced remodeling of a microenvironment that acts as a paracrine regulator to enrich CD44v6 (+) in colorectal CICs.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Robot-assisted D2 Total Gastrectomy With En Bloc Distal Splenopancreatectomy (SDCC - 32AB - Upper) - Aug 21, 2022 - Abstract #ACSCLINCON2022ACS_CLINCON_3340; (c) ResultsOne month postoperative the patient initiated FOLFOX chemotherapy and continued for 6 months. Pathology showed a tubular adenocarcinoma, grade 3 with invasion of the splenic capsule and peripancreatic adipose tissue, and metastasis to the adrenal gland.(d) ConclusionsThe use of magnified three-dimensional views from the robotic system and articulated movements of the robotic arms allows for this complex and challenging procedure to be more easily performed than the laparoscopic approach.
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Robotic Pancreaticoduodenectomy With Antrectomy For Locally Advanced Duodenal Adenocarcinoma (SDCC - 32AB - Upper) - Aug 21, 2022 - Abstract #ACSCLINCON2022ACS_CLINCON_3337; The patient tolerated the procedure well and went home on POD 4. This video shows the safety and feasibility of a robotic pancreaticoduodenectomy with antrectomy in a patient with locally advanced duodenal adenocarcinoma.
- |||||||||| methotrexate / Generic mfg.
Journal, IO biomarker: Methotrexate Inhibits T Cell Proliferation but Not Inflammatory Cytokine Expression to Modulate Immunity in People Living With HIV. (Pubmed Central) - Aug 17, 2022 This inhibitory effect was reversible with folinic acid, suggesting low-dose MTX exerts anti-inflammatory effects in vivo in PWH largely by blocking T cell proliferation via dihydrofolate reductase inhibition, yet daily administration of folic acid did not rescue this effect in trial participants. Our findings identify the main mechanism of action of this widely used anti-inflammatory medicine in PWH and may provide insight into how MTX works in the setting of other inflammatory conditions.
- |||||||||| Vectibix (panitumumab) / Amgen, Takeda
DRUG-INDUCED PNEUMONITIS IN THE SETTING OF SARS-COV-2 INFECTION (Convention Center Exhibit Hall: Poster Area) - Aug 16, 2022 - Abstract #CHEST2022CHEST_2545; Many chemotherapy agents have been implicated in drug related ILD such as bleomycin, taxanes...She was treated with remdesivir and dexamethasone, however her oxygen requirements continued to rapidly escalate...Given clinical history and imaging findings, diagnosis of ILD was suspected, and she was started on solumedrol 1 mg/kg...Approved by the US Food and Drug Administration in 2006 for advanced or recurrent colorectal cancer exhibiting wild-type KRAS mutation.2 ILD is rarely reported with panitumumab monotherapy, but higher incidence when used as a combination treatment such as with FOLFOX or FOLFIRI... Although the incidence of ILD is low, the mortality rate is high, therefore early recognition and treatment is associated with improved clinical outcomes.
- |||||||||| Avastin (bevacizumab) / Roche
AN UNUSUAL PRESENTATION OF COLON ADENOCARCINOMA (Convention Center Exhibit Hall: Poster Area) - Aug 16, 2022 - Abstract #CHEST2022CHEST_1982; Although rare, adenocarcinoma of the colon can present as cavitary pulmonary lesions without liver involvement. These lesions should be biopsied to rule out primary lung cancer before proceeding with treatment.
- |||||||||| irinotecan / Generic mfg.
Enrollment open: XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study) (clinicaltrials.gov) - Aug 15, 2022 P=N/A, N=24, Recruiting, Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2022 --> Dec 2023 Not yet recruiting --> Recruiting
- |||||||||| Mekinist (trametinib) / Novartis
Journal, Epigenetic controller: Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer. (Pubmed Central) - Aug 14, 2022 RNA-mediated gene silencing of p38α MAPK or its selective chemical inhibition, however, reduces LY6G6D expression, reducing trametinib's anti-inflammatory effects...We found that cancer-specific immunodominant epitopes are controlled by p38α MAPKs signaling and suppressed by DNA methylation in histological variants with Mucinous differentiation. This work provides a promising prospective for clinical application in diagnosis and personalized therapeutic strategies of colorectal cancer.
- |||||||||| Clinical, Retrospective data, Review, Journal: Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. (Pubmed Central) - Aug 14, 2022
Shortages led to delays in chemotherapy and changes in treatment or omission, complicated clinical research, and increased risk of medication errors and adverse outcomes. In conclusion, this NMA adds further evidence to the optimization of treatment strategies for gastric and GEJ adenocarcinomas and confirms that incorporation of perioperative triplet-based CT improved both OS and DFS compared to surgery alone and other preoperative strategies.
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. (Pubmed Central) - Aug 12, 2022 In conclusion, this NMA adds further evidence to the optimization of treatment strategies for gastric and GEJ adenocarcinomas and confirms that incorporation of perioperative triplet-based CT improved both OS and DFS compared to surgery alone and other preoperative strategies. Our findings support the application of CRISPR-Cas9 screening in identifying novel therapeutic targets and suggest new strategies for overcoming chemoresistance in pancreatic cancer.
|